LFCR רווח למניה בשנים עשר החודשים האחרונים Lifecore

Lifecore Biomedical (LFCR) maintains long-term orders for the filling of hyaluronic agents due to rigorous FDA validation. Stable plant utilization is ensured by its role as a contract manufacturer of complex injectables. The humanitarian status of medicine and Western supply chains minimize external risks. The value of 0.00 captures the current indicator magnitude, which can be tracked via the 12-month net income per share history.

Lifecore Biomedical's status as a strategic partner for pharmaceutical behemoths in the production of complex injectables guarantees high capacity utilization and a steady cash flow. The current value of 0.00 in the rolling earnings per share trend reflects the final capital efficiency for the year, allowing investors to assess the business's real margins and the fundamental resilience of the stock price against market volatility.